EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.

Swiss biotech Numab Therapeutics has raised an oversubscribed series C financing of CHF100m to accelerate the development of its multispecific antibodies, from investors attracted by the company’s thoughtful approach to developing its technology. 

Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.

The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations.